AZD1390   Click here for help

GtoPdb Ligand ID: 11277

Compound class: Synthetic organic
Comment: AZD1390 is an oral, brain-penetrant ATM kinase inhibitor [2]. Structurally, AZD1390 is from the same chemical series as AZD0156, but is optimised to cross the blood-brain barrier [3-4]. Mechanistically, blocking ATM disrupts DNA damage repair and sensitises cancer cells to radiotherapy. This induces G2 cell cycle arrest and the development of micronuclei, and ultimately leads to apoptosis. Experimental evidence suggests that AZD1390 is able to promote neurite outgrowth in vitro, and axon regeneration and functional recovery in in vivo models of spinal cord injury [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Click here for help
Canonical SMILES Fc1cc2ncc3c(c2cc1c1ccc(nc1)OCCCN1CCCCC1)n(C(C)C)c(=O)n3C
Isomeric SMILES Fc1cc2ncc3c(c2cc1c1ccc(nc1)OCCCN1CCCCC1)n(C(C)C)c(=O)n3C
InChI InChI=1S/C27H32FN5O2/c1-18(2)33-26-21-14-20(22(28)15-23(21)29-17-24(26)31(3)27(33)34)19-8-9-25(30-16-19)35-13-7-12-32-10-5-4-6-11-32/h8-9,14-18H,4-7,10-13H2,1-3H3
No information available.
Summary of Clinical Use Click here for help
AZD1390 has been advanced to clinical trials for non-small cell lung cancer and glioblastoma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04550104 A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC Phase 1 Interventional University of Leeds
NCT03423628 A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Phase 1 Interventional AstraZeneca